Navigation Links
Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
Date:10/11/2007

MALVERN, Pa., Oct. 11 /PRNewswire/ -- Solstice Neurosciences, Inc. ("Solstice") announced the appointment of Dennis L. Smith to its Board of Directors. Mr. Smith will serve as Executive Chairman replacing James Thomas, who remains on the Board having served as Chairman since Solstice was founded in July 2004.

Mr. Smith brings unique specialty pharmaceutical industry experience and expertise to Solstice that will be invaluable in providing guidance and leadership for growth and maximizing stockholder value. Mr. Smith will work with the Board and Solstice management to review current operations and develop strategic options.

Mr. Smith has worked in the pharmaceutical industry since 1973, and most recently served as President and Chief Executive Officer of INO Therapeutics LLC., a specialty pharmaceutical company with strengths in development, marketing, and sales of critical care drugs and drug/device combinations, and focused on making innovative therapies available to healthcare professionals and patients. Prior to INO, Mr. Smith spent 15 years with DuPont Pharmaceutical Company, where he served as President of U.S. Operations, Executive Vice President of Global Health Systems, Executive Vice President in Europe, and Vice President and General Manager in Canada, among numerous other positions at DuPont Pharmaceuticals and DuPont Merck. Mr. Smith was also employed at Baxter International and Sandoz Pharmaceuticals (now Novartis). Mr. Smith is a graduate of Michigan State University and the Lake Forest Graduate School of Business.

"We are extremely pleased to have Dennis join the Board of Directors of Solstice," said Shawn Patrick O'Brien, President and Chief Executive Officer. "His wide-ranging experience in the biopharmaceutical industry will undoubtedly prove to be extremely valuable as Solstice continues to evolve and broaden our product portfolio globally," Mr. O'Brien said.

"I am excited to be joining the Board and eager to work with Shawn and the Solstice team as well as the Board members to better understand this dynamic and growing business and help lead the future direction. I also look forward to interacting with employees and the customers who treat the patients we ultimately serve," said Mr. Smith.

About Solstice Neurosciences, Inc.

Founded in 2004, Solstice Neurosciences, Inc. is a biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty products. Solstice's first product, MYOBLOC(R) (Botulinum Toxin Type B) Injectable Solution, represents the only botulinum toxin type B currently available to physicians and patients. MYOBLOC is sold in the United States and approved in Canada. It is also distributed and sold in the EU as NeuroBloc. MYOBLOC is indicated for the treatment of patients with cervical dystonia (CD) to reduce the severity of abnormal head position and pain associated with CD. For more information about Solstice Neurosciences, Inc., visit http://www.solsticeneuro.com.

Myobloc(R) and NeuroBloc(R) are registered trademarks of Solstice Neurosciences, Inc.


'/>"/>
SOURCE Solstice Neurosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Local meteorology company accurately predicts Hurricane Dennis landfall
2. CIO Leadership Series: Greg Smith, Wheaton Franciscan Healthcare
3. GenTel acquires GlaxoSmithKline chip platform
4. Can you keep ahead of progress? An exclusive interview with Rick Smith of iNoc
5. VanderSanden appointed president of AT&T Wisconsin
6. Chemical-petroleum executive joins Virent Energy board
7. Visions: Matheys says CIO role is good training for executive suite
8. Biotech executive books a career flight thats closer to home
9. CEOs Gone Wild? Risks and rewards in the executive suite
10. Early-stage executives hear from investors
11. Pedlar the latest executive to leave Merge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... Austin, TX May 24, 2017 (PRWEB) , ... ... ... Require Constant Connectivity , Medical systems are increasingly being developed with Wi-Fi connectivity ... to be easily moved from room to room. In addition, compact mobile devices ...
(Date:5/23/2017)... , ... May 23, 2017 ... ... an unlimited source of human cardiovascular cells for research and the development ... makes it possible to generate large numbers of cardiomyocytes (hPSC-CMs). Due to ...
(Date:5/23/2017)... ... 23, 2017 , ... Vortex Biosciences , provider of circulating tumor cell ... tumor cells using Vortex microfluidic technology ” in Nature Precision Oncology on May 8th. ... Di Carlo and Dr. Matthew Rettig at the University of California, Los Angeles. The ...
(Date:5/23/2017)... ... , ... Cambridge Semantics , the leading provider of Big Data management ... and Expo in Boston May 23-25 with a featured speaker and solution demos ... Lake is also a finalist for the Best of Show award. , James LaPointe, ...
Breaking Biology Technology:
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
Breaking Biology News(10 mins):